Humasis Co

Humasis Co R&D / Revenue

The R&D to Revenue Ratio of Humasis Co (205470.KQ) as of Nov 10, 2026 is 1.35 %. In the previous year, R&D to Revenue Ratio was 6.01 % — a change of -77.53% (lower).

R&D / Revenue

1.35 %

YoY

-77.53%

Last updated:

R&D to Revenue Ratio of Humasis Co is 2025 1.35 % . R&D to Revenue Ratio of Humasis Co was 2024 6.01 % . It decreases by -77.53% lower compared to the previous year.

The Humasis Co R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2020
3.19 KRW
Jan 1, 2021
1.05 KRW
Jan 1, 2022
1.11 KRW
Jan 1, 2023
29.89 KRW
Jan 1, 2024
6.01 KRW
Jan 1, 2025
1.35 KRW
The Humasis Co R&D / Revenue history
YEARR&D / RevenueYoY
1.35 %-77.53%
6.01 %-79.89%
29.89 %+2,591.03%
1.11 %+5.98%
1.05 %-67.18%
3.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

R&D to Revenue Ratio of Humasis Co is 1.35 % in 2025.

R&D to Revenue Ratio of Humasis Co changed from 6.01 % to 1.35 %, representing a -77.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Humasis Co since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Humasis Co

All Key Metrics — Humasis Co